KALA BIO, Inc. (KALA)

6.94 +0.12 (+1.76%) 收市：04:00PM EDT

KALA BIO, Inc.

1167 Massachusetts Avenue
Arlington, MA 02476
United States
781 996 5252
https://www.kalarx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 43

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Mark T. Iwicki	Chairman & CEO	1.01M	無	1966
Mr. Todd Bazemore	President & COO	733.58k	無	1970
Dr. Kim Brazzell Ph.D.	Head of R&D and Chief Medical Officer	709.49k	無	1953
Dr. Justin Hanes Ph.D.	Founder & Chair of the Scientific Advisory Board	無	無	無
Ms. Mary Reumuth CPA	CFO & Treasurer	無	無	1975
Ms. Jill S. Steier	Executive Director of Investor Relations & Corporate Communications	無	無	無
Mr. Vincent Kosewski	Senior VP of Manufacturing & Supply Chain Management	無	無	1963
Mr. Darius Kharabi J.D., M.B.A.	Chief Business Officer	無	無	1980
Dr. Francis S. Mah M.D.	Chief Medical Advisor	無	無	無
Mr. Josiah Craver	Senior VP & Corporate Controller	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

公司管治

截至 無 止，KALA BIO, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。